AKT
ANXA2
ATC code L01
ATC code L04
Abatacept
Abemaciclib
Abetimus
Acalabrutinib
Adagrasib
Adalimumab
Adipotide
Adoptive cell transfer
Afatinib
Afelimomab
Aflibercept
Aging (journal)
Alectinib
Alefacept
Alemtuzumab
Alpelisib
American Society of Health-System Pharmacists
Amivantamab
Anakinra
Anaplastic lymphoma kinase
Anatomical Therapeutic Chemical Classification System
Anifrolumab
Anti-lymphocyte globulin
Anti-thymocyte globulin
Antibody
Antifolate
Antimetabolite
Antineoplastic
Apremilast
Asciminib
Aselizumab
Asia-Pacific
Atezolizumab
Atezolizumab/hyaluronidase
Atorolimumab
Aumolertinib
Avacopan
Avapritinib
Avelumab
Axatilimab
Axitinib
Azathioprine
BRAF (gene)
Baricitinib
Basigin
Basiliximab
Bcr-abl fusion protein
Begelomab
Belantamab mafodotin
Belatacept
Belimumab
Bermekimab
Bertilimumab
Bevacizumab
Bibcode (identifier)
Bimekizumab
Binimetinib
Biological half-life
Blinatumomab
Blisibimod
Bone Marrow Transplantation (journal)
Bosutinib
Boxed warning
Brentuximab vedotin
Briakinumab
Brigatinib
Brodalumab
Bruton's tyrosine kinase
C-Met
CAS Registry Number
CD117
CD11a
CD135
CD154
CD18
CD20
CD23
CD30
CD33
CD3 (immunology)
CD4
CD40 (protein)
CD52
CD80
CDK inhibitor
CTLA-4
Cabozantinib
Calcineurin
Canakinumab
Cancer immunotherapy
Capmatinib
Cardiac allograft vasculopathy
Catumaxomab
Cedelizumab
Cediranib
Cemiplimab
Ceritinib
Certolizumab pegol
Cetuximab
ChEBI
ChEMBL
ChemSpider
Chemical formula
Chloramphenicol acetyltransferase
Ciclosporin
Clenoliximab
ClinicalTrials.gov
Cobimetinib
CompTox Chemicals Dashboard
Complement component 5
Copanlisib
Cosibelimab
Crizotinib
Crovalimab
Cyclophilin
Dabrafenib
Daclizumab
Dacomitinib
Dactolisib
DailyMed
Dalpiciclib
Danicopan
Daratumumab
Darvadstrocel
Dasatinib
Denileukin diftitox
Deucravacitinib
Deuruxolitinib
Dihydroorotate dehydrogenase
Dimethyl fumarate
Dinutuximab beta
Diroximel fumarate
Doi (identifier)
Dostarlimab
Drug-eluting stent
DrugBank
Drug nomenclature
Drugs.com
Durvalumab
Duvelisib
ECHA InfoCard
EML4
Eculizumab
Edrecolomab
Efalizumab
Efgartigimod alfa
Efgartigimod alfa/hyaluronidase
Elotuzumab
Elranatamab
Elsilimomab
Emapalumab
Encorafenib
Enfortumab vedotin
Entrectinib
EpCAM
Epcoritamab
Epidermal growth factor receptor
ErbB
Erdafitinib
Erlizumab
Erlotinib
Etanercept
Etrasimod
Everolimus (data page)
Exemestane
Exotoxin
FDA
FKBP
FKBP12
Faralimomab
Fedratinib
Fibroblast growth factor receptor
Filgotinib
Fingolimod
Fontolizumab
Food and Drug Administration
Frexalimab
Fruquintinib
Fusion protein
Futibatinib
Galiximab
Gastric cancer
Gavilimomab
Gefitinib
Gemtuzumab ozogamicin
Generic medication
Gilteritinib
Glasdegib
Glofitamab
Glucose intolerance
Golimumab
Gomiliximab
Graft-versus-host disease
Guselkumab
Gusperimus
HER2/neu
Hdl (identifier)
Hedgehog signaling pathway
Hepatocellular carcinoma
IL-2 receptor
ISBN (identifier)
IUPAC nomenclature of chemistry
Ibritumomab tiuxetan
Ibrutinib
Icotinib
Idelalisib
Imatinib
Immunoglobulin E
Immunomodulatory imide drug
Immunosenescence
Immunosuppression
Immunosuppressive drug
Inavolisib
Inebilizumab
Infigratinib
Infliximab
Influenza vaccine
Inolimomab
Inotuzumab ozogamicin
Integrin
Interferon
Interleukin
Interleukin-6 receptor
Interleukin 12
Interleukin 13
Interleukin 17
Interleukin 1 receptor antagonist
Interleukin 2
Interleukin 23
Interleukin 5
Interleukin 6
International Chemical Identifier
Ipilimumab
Iptacopan
Isatuximab
Itacitinib
Ixekizumab
JCI Insight
JSmol
Janus kinase
KEGG
KRAS
Keliximab
L-selectin
Lapatinib
Larotrectinib
Lazertinib
Lebrikizumab
Leflunomide
Lenalidomide
Lenvatinib
Lerdelimumab
Lestaurtinib
Leukemia
Loncastuximab tesirine
Lorlatinib
Lumiliximab
Lymphatic system
Lymphocyte function-associated antigen 1
Lymphoma
MEN1
MTOR
MTORC1
MTORC2
MTOR inhibitor
Macrolide
Mammalian target of rapamycin
Masitinib
Maslimomab
Mechanistic target of rapamycin
Medication
MedlinePlus
Mepolizumab
Metelimumab
Methotrexate
Midostaurin
Mirvetuximab soravtansine
Mitogen-activated protein kinase kinase
Mobocertinib
Mogamulizumab
Molar mass
Momelotinib
Monoclonal antibody
Monoclonal antibody therapy
Morolimumab
Mosunetuzumab
Moxetumomab pasudotox
Muromonab-CD3
Mycophenolic acid
Myeloid
NHS England
Natalizumab
Naxitamab
Necitumumab
Negative feedback
Neratinib
Nerelimomab
Netakimab
Neuroendocrine tumor
Nilotinib
Nintedanib
Nivolumab
Non-receptor tyrosine kinase
Novartis
Obinutuzumab
Ocrelizumab
Ocrelizumab/hyaluronidase
Odronextamab
Odulimomab
Ofatumumab
Olaratumab
Olmutinib
Olokizumab
Omalizumab
Opinercept
Oportuzumab monatox
Oral administration
Orelabrutinib
Organ transplant
Osimertinib
Otelixizumab
Ozanimod
PDE4 inhibitor
PMC (identifier)
PMID (identifier)
Pacritinib
Palbociclib
Pancreatic neuroendocrine tumor
Panitumumab
Parsaclisib
Pascolizumab
Pazopanib
Peficitinib
Pegcetacoplan
Pembrolizumab
Pemigatinib
Pertuzumab
Pexelizumab
Pexidartinib
Pharmacokinetics
Phases of clinical research
Pi3K inhibitor
Pimecrolimus
Pirfenidone
Pirtobrutinib
Platelet-derived growth factor receptor
Polatuzumab vedotin
Polyclonal antibodies
Pomalidomide
Ponatinib
Ponesimod
Pralsetinib
Pregnancy category
Proapoptotic
Progression-free survival
Prohibitin
Prolgolimab
PubChem
Purine synthesis inhibitor
Quizartinib
RET proto-oncogene
RTK class III
Radotinib
Ramucirumab
Rapamycin
Ravulizumab
Receptor tyrosine kinase
Regorafenib
Regulation of therapeutic goods
Repotrectinib
Reslizumab
Restenosis
Retifanlimab
Revumenib
Ribociclib
Ridaforolimus
Rilonacept
Ripretinib
Risankizumab
Ritlecitinib
Rituximab
Rociletinib
Route of administration
Rovelizumab
Rozanolixizumab
Ruplizumab
Ruxolitinib
S2CID (identifier)
Sabatolimab
Sacituzumab govitecan
Sarilumab
Satralizumab
Secukinumab
Selpercatinib
Selumetinib
Semaxanib
Serplulimab
Siltuximab
Simplified molecular-input line-entry system
Siplizumab
Siponimod
Sirolimus
Sirukumab
Sonidegib
Sorafenib
Sotorasib
Spesolimab
Src (gene)
Standard for the Uniform Scheduling of Medicines and Poisons
Subependymal giant cell astrocytoma
Sugemalimab
Sunitinib
Sutimlimab
TNF inhibitor
TSC1
TSC2
T cell
Tacrolimus
Tafasitamab
Talizumab
Talquetamab
Targeted cancer therapy
Targeted therapy
Tarlatamab
Tebentafusp
Teclistamab
Telimomab aritox
Telitacicept
Temsirolimus
Teneliximab
Teplizumab
Tepotinib
Teprotumumab
Teriflunomide
Thalidomide
Tildrakizumab
Tislelizumab
Tisotumab vedotin
Tivozanib
Toceranib
Tocilizumab
Tofacitinib
Toralizumab
Toripalimab
Tositumomab
Trametinib
Transplant rejection
Trastuzumab
Trastuzumab/hyaluronidase
Trastuzumab deruxtecan
Trastuzumab emtansine
Tremelimumab
Trilaciclib
Tuberous Sclerosis
Tuberous Sclerosis Complex
Tuberous sclerosis
Tuberous sclerosis complex
Tucatinib
Tumor-infiltrating lymphocytes
Tyrosine kinase inhibitor
Ublituximab
Umirolimus
Unique Ingredient Identifier
Upadacitinib
Ustekinumab
VEGF receptors
Vandetanib
Vapaliximab
Vascular endothelial growth factor
Vascular endothelial growth factor A
Vedolizumab
Vemurafenib
Venetoclax
Vepalimomab
Visilizumab
Vismodegib
Voclosporin
WHO Model List of Essential Medicines
World Health Organization
Zanidatamab
Zanolimumab
Zanubrutinib
Zenocutuzumab
Zolbetuximab
Zolimomab aritox
Zotarolimus